New PSMA PET/CT-Based AI Tool May Facilitate Monitoring of Treatment Response in Patients with PCa

Nucs AI has launched the artificial intelligence (AI)-powered TrackPSMA, which reportedly enables more timely clinician monitoring of radioligand treatment response in patients with prostate cancer (PCa).

Emphasizing research that has shown a significant number of patients may not have any benefit from radioligand treatment, Nucs AI said TrackPSMA provides AI automated longitudinal evaluation in seconds for prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) scans.

In addition to facilitating comparative assessments to help gauge treatment response, TrackPSMA incorporates individual lesion tracking into the longitudinal analysis, according to Nucs AI.

“Being able to track disease progression lesion by lesion represents a fundamental shift in how experts understand and manage cancer over time,” said Farid Yagubbayli, the chief technology officer for Nucs AI. “For the first time, we can measure therapy response objectively and reproducibly across scans, sites, and timepoints. It turns what was once a subjective visual comparison into a standardized, data-driven process that helps physicians act faster and with greater confidence.”